Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy
RAF and RENO-EXTEND Investigators*,Pietro Caliandro,Virginia Cancelloni,Moci Marco,Giuseppe Reale,Aurelia Zauli,Giancarlo Agnelli,Valeria Caso,Cecilia Becattini,Paolo Calabresi,Maria Giulia Mosconi,Michela Giustozzi,Georgios Tsivgoulis,David Julian Seiffge,Stefan T Engelter,Philippe Lyrer,Alexandros A Polymeris,Tolga Dittrich,Annaelle Zietz,Gian Marco De Marchis,Jukka Putaala,Daniel Strbian,Liisa Tomppo,Patrik Michel,Davide Strambo,Alexander Salerno,Suzette Remillard,Manuela Buehrer,Odessa Bavaud,Peter Vanacker,Susanna Zuurbier,Laetitia Yperzeele,Caroline M J Loos,Manuel Cappellari,Andrea Emiliani,Marialuisa Zedde,Azmil Abdul-Rahim,Jesse Dawson,Robert Cronshaw,Erika Schirinzi,Massimo Del Sette,Christoph Stretz,Narendra Kala,Michael Reznik,Ashley Schomer,Brian Mac Grory,Mahesh Jayaraman,Ryan McTaggart,Shadi Yaghi,Karen L Furie,Luca Masotti,Elisa Grifoni,Danilo Toni,Angela Risitano,Anne Falcou,Luca Petraglia,Enrico Maria Lotti,Marina Padroni,Lucia Pavolucci,Piergiorgio Lochner,Giorgio Silvestrelli,Alfonso Ciccone,Andrea Alberti,Michele Venti,Ilaria Leone De Magistris,Odysseas Kargiotis,Alessandro Rocco,Marina Diomedi,Simona Marcheselli,Kateryna Antonenko,Eugenia Rota,Tiziana Tassinari,Valentina Saia,Francesco Palmerini,Paolo Aridon,Valentina Arnao,Serena Monaco,Salvatore Cottone,Antonio Baldi,Cataldo D'Amore,Walter Ageno,Samuela Pegoraro,George Ntaios,Dimitrios Sagris,Sotirios Giannopoulos,Maria Kosmidou,Evangelos Ntais,Michele Romoli,Leonardo Pantoni,Silvia Rosa,Pierluigi Bertora,Alberto Chiti,Isabella Canavero,Carlo Emanuele Saggese,Maurizio Plocco,Elisa Giorli,Lina Palaiodimou,Eleni Bakola,Fabio Bandini,Antonio Gasparro,Valeria Terruso,Marina Mannino,Alessandro Pezzini,Raffaele Ornello,Simona Sacco,Nemanja Popovic,Umberto Scoditti,Antonio Genovese,Licia Denti,Yuriy Flomin,Michelangelo Mancuso,Elena Ferrari,Maria Chiara Caselli,Leonardo Ulivi,Nicola Giannini,Kostantinos Vadikolias,Chrysoula Liantinioti,Maria Chondrogianni,Panagiotis Halvatsiotis,Monica Carletti,Efstathia Karagkiozi,George Athanasakis,Kostantinos Makaritsis,Alessia Lanari,Turgut Tatlisumak,Monica Acciarresi,Vieri Vannucchi,Gianni Lorenzini,Rossana Tassi,Francesca Guideri,Maurizio Acampa,Giuseppe Martini,Sung-Il Sohn,Nicola Mumoli,Prasanna Tadi,Federica Letteri,Miriam Maccarrone,Loris Poli,Mauro Magoni,Franco Galati,Cindy Tiseo,Vanessa Gourbali,Giovanni Orlandi,Martina Giuntini,Francesco Corea,Marta Bellesini,Laura Girardi,Mario Maimone Baronello,Theodore Karapanayiotides,Christina Rueckert,Laszló Csiba,Lilla Szabó,Alberto Rigatelli,Davide Imberti,Dorjan Zabzuni,Alessio Pieroni,Kristian Barlinn,Lars-Peder Pallesen,Jessica Barlinn,Boris Doronin,Vera Volodina,Dirk Deleu,Bruno Bonetti,Cesare Porta,Luana Gentile,Ashraf Eskandari,Maurizio Paciaroni
DOI: https://doi.org/10.1177/23969873231183211
Abstract:Introduction: Ischaemic stroke patients with atrial fibrillation (AF) are at high risk of stroke recurrence despite oral anticoagulation therapy. Patients with cardiovascular comorbidities may take both antiplatelet and oral anticoagulation therapy (OAC/AP). Our study aims to evaluate the safety and efficacy of OAC/AP therapy as secondary prevention in people with AF and ischaemic stroke. Patients and methods: We performed a post-hoc analysis of pooled individual data from multicenter prospective cohort studies and compared outcomes in the OAC/AP cohort and patients on DOAC/VKA anticoagulation alone (OAC cohort). Primary outcome was a composite of ischaemic stroke, systemic embolism, intracranial bleeding, and major extracranial bleeding, while secondary outcomes were ischaemic and haemorrhagic events considered separately. A multivariable logistic regression analysis was performed to identify independent predictors for outcome events. To compare the risk of outcome events between the two cohorts, the relation between the survival function and the set of explanatory variables were calculated by Cox proportional hazard models and the results were reported as adjusted hazard ratios (HR). Finally another analysis was performed to compare the overall risk of outcome events in both OAC/AP and OAC cohorts after propensity score matching (PSM). Results: During a mean follow-up time of 7.5 ± 9.1 months (median follow-up time 3.5 months, interquartile range ±3), 2284 stroke patients were on oral anticoagulants and 215 were on combined therapy. The multivariable model demonstrated that the composite outcome is associated with age (OR: 1.03, 95% CI: 1.01-1.04 for each year increase) and concomitant antiplatelet therapy (OR: 2.2, 95% CI: 1.48-3.27), the ischaemic outcome with congestive heart failure (OR: 1.55, 95% CI: 1.02-2.36) and concomitant antiplatelet therapy (OR: 1.93, 95% CI: 1.19-3.13) and the haemorrhagic outcome with age (OR: 1.03, 95% CI: 1.01-1.06 for each year increase), alcoholism (OR: 2.15, 95% CI: 1.06-4.39) and concomitant antiplatelet therapy (OR: 2.22, 95% CI: 1.23-4.02). Cox regression demonstrated a higher rate of the composite outcome (hazard ratio of 1.93 [95% CI, 1.35-2.76]), ischaemic events (HR: 2.05 [95% CI: 1.45-2.87]) and bleeding outcomes (HR: 1.90 [95% CI, 1.06-3.40]) in OAC/AP cohort. After PSM analysis, the composite outcome remained more frequent in people treated with OAC + AP (RR: 1.70 [95% CI, 1.05-2.74]). Discussion: Secondary prevention with combination of oral anticoagulant and antiplatelet therapy after ischaemic stroke was associated with worse outcomes in our cohort. Conclusion: Further research is needed to improve secondary prevention by investigating the mechanisms of recurrent ischaemic stroke in patients with atrial fibrillation.